Gincy is a Senior Epidemiologist and the Real World Evidence Partnership Lead of the Transforming cancer OUtcomes through Research (TOUR) team, with expertise in pharmacoepidemiology. She collaborates internationally with research institutions, healthcare providers, and industry partners to leverage real-world data and generate actionable insights that inform clinical practice.

Gincy leads several partnership projects within the Guy’s Real World Evidence Programme, including the investigation of treatment patterns and clinical outcomes for various tumour types such as colorectal cancer, hepatocellular carcinoma, and prostate cancer. She also oversees the setup and maintenance of the national DPYD registry and the cardio-oncology database, with a focus on clinically significant outcomes.

Working in collaboration with Professor Ton Coolen’s team, Gincy applies advanced mathematical theory of overfitting in regression models for time-to-event cancer data within the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) database. She further supports the European Academy of Allergy and Clinical Immunology’s AllergoOncology group by providing expertise in study design, statistical advice, and analysis to explore the unique immunologic interface between allergy, IgE immune responses, and oncology.